Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.

Similarly, in the Pembrolizumab + Docetaxel group, non-responders showed a trend towards increased EV PD-L1 in comparison to responders ( p = 0.050) (Fig. 3 E) while no differences were observed in the Docetaxel treated patients (Fig. 3 F).

also in 53,322 other papers